Examining how Johnson & Johnson, Boston Scientific, and Abbott are positioning themselves in the IVL market through key acquisitions and a comparative analysis of their
The U.S. Food and Drug Administration (FDA) has decided not to approve etripamil, a nasal spray developed by Milestone Pharmaceuticals for treating heart rhythm issues,
Semaglutide, a GLP-1 receptor agonist marketed by Novo Nordisk under the names Wegovy and Ozempic, has demonstrated significant health benefits for patients with both type
Artificial intelligence (AI) is revolutionizing cardiovascular imaging and interventional cardiology, driving significant improvements in diagnostic accuracy, workflow efficiency, and treatment precision. An analysis published in
Abbott’s TriClip system has shown significant, sustained improvements in the treatment of tricuspid regurgitation (TR), according to data from the TRILUMINATE pivotal trial. The study
Boston Scientific has received FDA 510(k) clearance for its Bolt intravascular lithotripsy (IVL) system, marking a significant milestone in its vascular treatment portfolio. The system,
Stay ahead in MedTech with industry updates, breakthroughs, and expert
insights—delivered straight to your inbox.
© 2025 MEDWIRE.AI. All rights reserved. MEDWIRE.AI is a trusted source for MedTech news and insights. Our website content and services are for informational purposes only. MEDWIRE.AI does not provide medical advice, diagnosis, or treatment.
